{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:31:44Z","timestamp":1790443904055,"version":"4.1.0"},"reference-count":50,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Infirmary Cancer Care"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Purpose: SMARCA4-deficient carcinomas are rare, aggressive malignancies characterized by loss of BRG1, a core component of the SWI\/SNF chromatin remodeling complex. These typically arise in the chest, but recent case reports suggest rare involvement of the gastrointestinal tract, particularly the small intestine. This review aims to consolidate the available literature on SMARCA4-deficient carcinomas of the small intestine, highlighting their clinical, histopathological, molecular, and therapeutic features. Design: A systematic review of PubMed was conducted through March 2025 to identify all published cases of primary SMARCA4-deficient carcinomas of the small intestine. Inclusion criteria required immunohistochemical or molecular confirmation of SMARCA4\/BRG1 loss. Studies describing metastases, non-small intestine primaries, or lacking molecular data were excluded. Ten eligible cases were analyzed in detail. Results: Patients were predominantly male (9 out of 10) with a median age of 54 years. Most carcinomas arose in the duodenum and patients frequently presented with nonspecific symptoms and advanced-stage disease. Histologically, tumors demonstrated undifferentiated or rhabdoid features with high mitotic activity and extensive necrosis. Immunohistochemistry confirmed loss of SMARCA4, while several cases also showed SMARCA2 loss. Molecular profiling revealed congruent mutations in TP53 and CTNNB1, among oncogenic drivers. While some patients with localized disease achieved prolonged survival after surgery and adjuvant chemotherapy, those with metastatic disease had limited responses to immune checkpoint inhibitors, despite PD-L1 positivity in a subset. Overall survival ranged from 2 to 29 months. Conclusions: SMARCA4-deficient carcinomas of the small intestine represent a distinct, high-grade malignancy with poor prognosis and limited therapeutic options. Prompt recognition, SMARCA4 testing, and referral to specialized centers are essential. Prospective studies are needed to guide therapy and explore targeted approaches in this challenging carcinoma subtype.<\/jats:p>","DOI":"10.3390\/curroncol33020107","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T11:16:38Z","timestamp":1770722198000},"page":"107","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["SMARCA4-Deficient Carcinomas of the Small Intestine: A Systematic Review"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9128-1023","authenticated-orcid":false,"given":"Aaqid","family":"Syed","sequence":"first","affiliation":[{"name":"Mobile Infirmary Medical Center, Mobile, AL 36607, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanis","family":"Boumber","sequence":"additional","affiliation":[{"name":"Thoracic Medical Oncology Section, Phase 1 Unit, O\u2019Neal Comprehensive Cancer Center, UAB Heersink School of Medicine, Birmingham, AL 35233, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midhun","family":"Malla","sequence":"additional","affiliation":[{"name":"Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA"},{"name":"GI Medical Oncology, O\u2019Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35233, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13000-021-01091-6","article-title":"Undifferentiated colonic neoplasm with SMARCA4 germline gene mutation and loss of SMARCA4 protein expression: A case report and literature review","volume":"16","author":"Duan","year":"2021","journal-title":"Diagn. Pathol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Peng, L., Li, J., Wu, J., Xu, B., Wang, Z., Giamas, G., Stebbing, J., and Yu, Z. (2021). A Pan-Cancer Analysis of SMARCA4 Alterations in Human Cancers. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.762598"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1038\/s41598-018-20217-3","article-title":"High expression of SMARCA4 or SMARCA2 is frequently associated with an opposite prognosis in cancer","volume":"8","author":"Reyes","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_4","first-page":"e30708","article-title":"SMARCA4-Deficient Undifferentiated Tumor: A Rare Malignancy With Distinct Clinicopathological Characteristics","volume":"14","year":"2022","journal-title":"Cureus"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.bbagrm.2012.02.019","article-title":"Chromatin remodeling during glucocorticoid receptor regulated transactivation","volume":"1819","author":"King","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/00000478-199411000-00004","article-title":"Small Cell Carcinoma of the Ovary, Hypercalcemic Type","volume":"18","author":"Young","year":"1994","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/ng.2922","article-title":"Recurrent SMARCA4 mutations in small cell carcinoma of the ovary","volume":"46","author":"Jelinic","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.anndiagpath.2015.04.001","article-title":"Pattern of SMARCB1 (INI1) and SMARCA4 (BRG1) in poorly differentiated endometrioid adenocarcinoma of the uterus: Analysis of a series with emphasis on a novel SMARCA4-deficient dedifferentiated rhabdoid variant","volume":"19","author":"Strehl","year":"2015","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/PAT.0000000000000270","article-title":"SWI\/SNF complex deficiency and mismatch repair protein expression in undifferentiated and dedifferentiated endometrial carcinoma","volume":"47","author":"Stewart","year":"2015","journal-title":"Pathology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5858\/arpa.2019-0633-OA","article-title":"SMARCA4\/BRG1\u2013Deficient Non\u2013Small Cell Lung Carcinomas: A Case Series and Review of the Literature","volume":"145","author":"Nambirajan","year":"2020","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/ng.3399","article-title":"SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas","volume":"47","author":"Watson","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/PAS.0000000000000554","article-title":"SWI\/SNF Complex\u2013deficient Undifferentiated\/Rhabdoid Carcinomas of the Gastrointestinal Tract","volume":"40","author":"Agaimy","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/PAS.0000000000001836","article-title":"SWI\/SNF Complex-deficient Undifferentiated Carcinoma of the Gastrointestinal Tract","volume":"46","author":"Chang","year":"2022","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2019","journal-title":"Histopathology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6814","DOI":"10.1038\/s41467-022-34562-5","article-title":"Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers","volume":"13","author":"Cantley","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.radcr.2023.11.038","article-title":"SMARCA4-deficient tumors in the adrenal gland and small intestines: A rare case report","volume":"19","author":"Kambe","year":"2024","journal-title":"Radiol. Case Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s12328-023-01853-3","article-title":"Diagnosis and management of gastrointestinal SMARCA4-deficient undifferentiated tumors","volume":"16","author":"Wang","year":"2023","journal-title":"Clin. J. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"456","DOI":"10.5306\/wjco.v15.i3.456","article-title":"PD-1 antibody in combination with chemotherapy for the treatment of SMARCA4-deficient advanced undifferentiated carcinoma of the duodenum: Two case reports","volume":"15","author":"Shi","year":"2024","journal-title":"World J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41417-024-00732-4","article-title":"The golden key to open mystery boxes of SMARCA4-deficient undifferentiated thoracic tumor: Focusing immunotherapy, tumor microenvironment and epigenetic regulation","volume":"31","author":"Li","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/jjco\/hyad175","article-title":"the Lung Cancer Study Group of the Japan Clinical Oncology Group (JCOG). Thoracic SMARCA4-Deficient Undifferentiated Tumor: Current Knowledge and Future Perspectives","volume":"54","author":"Shinno","year":"2023","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jtho.2021.09.017","article-title":"Introduction to 2021 WHO Classification of Thoracic Tumors","volume":"17","author":"Tsao","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1111\/1759-7714.13215","article-title":"Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: A case report","volume":"10","author":"Takada","year":"2019","journal-title":"Thorac. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/annonc\/mdz160","article-title":"Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor","volume":"30","author":"Henon","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1097\/PAS.0000000000000285","article-title":"SMARCB1 (INI-1)-deficient Carcinomas of the Sinonasal Tract","volume":"38","author":"Bishop","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/his.14096","article-title":"Loss of switch\/sucrose non-fermenting complex protein expression in undifferentiated gastrointestinal and pancreatic carcinomas","volume":"77","author":"Schaeffer","year":"2020","journal-title":"Histopathology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/cas.14301","article-title":"Solid-type poorly differentiated adenocarcinoma of the stomach: Deficiency of mismatch repair and SWI\/SNF complex","volume":"111","author":"Tsuruta","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/his.14117","article-title":"The clinicopathological and molecular analysis of gastric cancer with altered SMARCA4 expression","volume":"77","author":"Huang","year":"2020","journal-title":"Histopathology"},{"key":"ref_28","unstructured":"McManus, L.M., and Mitchell, R.N. (2014). Surgical pathology of sarcomas. Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms, Academic Press."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/cncy.22709","article-title":"Diagnosis of thoracic SMARCA4-deficient undifferentiated tumor in cytology","volume":"131","author":"Kezlarian","year":"2023","journal-title":"Cancer Cytopathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1097\/PAS.0000000000000173","article-title":"SMARCB1 (INI1)-negative Rhabdoid Carcinomas of the Gastrointestinal Tract","volume":"38","author":"Agaimy","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.humpath.2017.05.024","article-title":"SMARCA4-deficient thoracic sarcoma: Report of a case and insights into how to reach the diagnosis using limited samples and resources","volume":"70","author":"Kuwamoto","year":"2017","journal-title":"Hum. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Meng, X., Ma, J., Meng, N., Yun, T., and Niu, B. (2023). Case Report: SMARCA4 (BRG1)-deficient undifferentiated carcinoma of gallbladder with genetic analysis. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1086266"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"108817","DOI":"10.1016\/j.lungcan.2025.108817","article-title":"The immune desert tumor microenvironment in Thoracic SMARCA4-deficient undifferentiated tumors: Spatial distribution characteristics and prognostic significance","volume":"210","author":"Wang","year":"2025","journal-title":"Lung Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1158\/1078-0432.CCR-18-3778","article-title":"Immune Exclusion-Wnt\/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC","volume":"25","author":"Llovet","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa2402141","article-title":"Nivolumab plus Ipilimumab in Microsatellite-Instability\u2013High Metastatic Colorectal Cancer","volume":"391","author":"Elez","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): Final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e000779","DOI":"10.1136\/jitc-2020-000779","article-title":"Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: A prospective study","volume":"8","author":"Kobayashi","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e002472","DOI":"10.1136\/jitc-2021-002472","article-title":"Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival","volume":"9","author":"Patel","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): A randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Di Nardo, P., Garattini, S.K., Torrisi, E., Fanotto, V., Miolo, G., Buonadonna, A., and Puglisi, F. (2022). Systemic Treatments for Advanced Small Bowel Adenocarcinoma: A Systematic Review. Cancers, 14.","DOI":"10.3390\/cancers14061502"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/1759-7714.13070","article-title":"Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: A case report","volume":"10","author":"Naito","year":"2019","journal-title":"Thorac. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1158\/1078-0432.CCR-20-1825","article-title":"The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_44","unstructured":"(2025, April 16). Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05286801."},{"key":"ref_45","unstructured":"(2025, April 16). A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06560645."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"B113","DOI":"10.1158\/1535-7163.TARG-23-B113","article-title":"Abstract B113: Discovery of PRT3789, a first-in-class potent and selective SMARCA2 degrader in clinical trials for the treatment of patients with SMARCA4 mutated cancers","volume":"22","author":"Ito","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"PR015","DOI":"10.1158\/1538-8514.SYNTHLETH24-PR015","article-title":"Abstract PR015: Discovery of LY4050784 (FHD-909), a selective BRM (SMARCA2) ATPase inhibitor for the treatment of BRG1 (SMARCA4) mutant cancers","volume":"23","author":"Lee","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12672-023-00639-w","article-title":"Thoracic SMARCA4-deficient undifferentiated tumor","volume":"14","author":"Jiang","year":"2023","journal-title":"Discov. Oncol."},{"key":"ref_49","unstructured":"(2025, April 16). Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03213665."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2217\/imt-2019-0142","article-title":"Notable response to nivolumab during the treatment of SMARCA4-deficient thoracic sarcoma: A case report","volume":"12","author":"Iijima","year":"2020","journal-title":"Immunotherapy"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/2\/107\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T12:02:36Z","timestamp":1770724956000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/2\/107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["curroncol33020107"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33020107","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]}}}